EPAS1 and renal cell carcinoma: In vitro studies of temsirolimus in renal cell carcinoma cell lines showed reduction of hypoxia‐inducible factors HIF‐1 and HIF‐2 alpha, and the vascular endothelial growth factor (VEGF).